A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down Syndrome Mouse Model
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Individuals with Down syndrome (DS) acquire Alzheimer's-like dementia (AD) and associated neuropathology earlier and at significantly greater rates than age-matched normosomic individuals. However, biological mechanisms have not been discovered and there is currently limited therapy for either DS- or AD-related dementia. Segmental trisomy 16 (Ts65Dn) mice provide a useful model for many of the degenerative changes which occur with age in DS including cognitive deficits, neuroinflammation, and degeneration of basal forebrain cholinergic neurons. Loss of noradrenergic locus coeruleus (LC) neurons is an early event in AD and in DS, and may contribute to the neuropathology. We report that Ts65Dn mice exhibit progressive loss of norepinephrine (NE) phenotype in LC neurons. In order to determine whether LC degeneration contributes to memory loss and neurodegeneration in Ts65Dn mice, we administered the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4; 2 doses of 50 mg/kg, i.p.) to Ts65Dn mice at four months of age, prior to working memory loss. At eight months of age, Ts65Dn mice treated with DSP-4 exhibited an 80% reduction in hippocampal NE, coupled with a marked increase in hippocampal neuroinflammation. Noradrenergic depletion also resulted in accelerated cholinergic neuron degeneration and a further impairment of memory function in Ts65Dn mice. In contrast, DSP-4 had minimal effects on normosomic littermates, suggesting a disease-modulated vulnerability to NE loss in the DS mouse model. These data suggest that noradrenergic degeneration may play a role in the progressive memory loss, neuroinflammation, and cholinergic loss occurring in DS individuals, providing a possible therapeutic avenue for future clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“IL-1 levels in the temporal lobe are elevated prior to AD-like pathology in DS [52], proposing a central role for this pro-inflammatory cytokine in propelling neuropathological pathways.”
Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4308-05.2006 · Cited by 684
Hock, C., Heese, K., Hulette, C., Rosenberg, C., & Otten, U. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.846 · Cited by 523 · cited 1×
“Together, these studies combined with our findings suggest that the reduced levels of BDNF observed with aging and in AD and Parkinson’s disease [61] may, at least in part, stem from disruptions in noradrenergic signaling.”
Locus coeruleus and regulation of behavioral flexibility and attention
(2000) · Progress in Brain Research · doi:10.1016/s0079-6123(00)26013-5 · Cited by 400
Self-citationGrudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396 · cited 1×
“LC neuronal loss is an early event in AD, noted even in patients with mild cognitive impairment [3].”
Cirelli, C., & Tononi, G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09187.2000 · Cited by 369 · cited 1×
“We also evaluated mRNA expression of brain-derived neurotrophic factor (BDNF), a neurotrophin heavily regulated by NE input into the hippocampus, as demonstrated by us and others [40].”
Morris, R. G. M., Inglis, J., Ainge, J. A., Olverman, H. J., Tulloch, J., Dudai, Y., & Kelly, P. A. T. (2006) · Neuron · doi:10.1016/j.neuron.2006.04.012 · Cited by 342
Cooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336 · cited 1×
“These mice recapitulate several of the degenerative hallmarks in DS individuals, including [12, 13], and age-dependent degeneration of cholinergic neurons [14].”
Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldiks, N., Zimmer, A., Hoehn, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4236-05.2006 · Cited by 305 · cited 4×
“Previous studies in A PP23 mice have indicated that NE depletion reduces the number of cholinergic terminals [22].”
InfluentialNEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE
Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P., & Hauser, D. L. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701040-00005 · Cited by 166 · cited 1×
“The loss of LC neurons correlates with dementia severity, as well as amyloid plaques and neurofibrillary tangles [4].”
Cited by
Functional neuroanatomy of the central noradrenergic system
Szabadi, E. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113490326 · Cited by 335
Down syndrome and Alzheimer's disease: common pathways, common goals
Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290
Self-citationAtas-Ozcan, H., Brault, V., Duchon, A., & Herault, Y. (2021) · Genes · doi:10.3390/genes12111833 · Cited by 78
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome
Hamlett, E. D., Hjorth, E., Ledreux, A., Gilmore, A., Schultzberg, M., & Granholm, A. C. (2020) · Glia · doi:10.1002/glia.23779 · Cited by 34
Self-citation
Metadata
- Authors
- Lockrow, J., Boger, H., Gerhardt, G., Aston-Jones, G., Bachman, D., & Granholm, A.-C.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-02-14
- Volume
- 23
- Issue
- 3
- Pages
- 471-489
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1883094711
- Cited by
- 49
- References
- 11
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down Syndrome Mouse Model. https://app.cochat.ai/papers/10.3233/jad-2010-101218
- The paper
- Lockrow, J., Boger, H., Gerhardt, G., Aston-Jones, G., Bachman, D., & Granholm, A.-C. (2011). A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down Syndrome Mouse Model. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-101218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.